- Home
- CGEN
CGEN
Compugen Ltd.
as 12-17-2024 4:00pm EST
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
| Founded: | 1993 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 142.8M | IPO Year: | 2000 |
| Target Price: | $4.00 | AVG Volume (30 days): | 445.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.35 - $3.03 | Next Earning Date: | 11-12-2024 |
| Revenue: | $59,852,000 | Revenue Growth: | 698.03% |
| Revenue Growth (this year): | 57.27% | Revenue Growth (next year): | -21.74% |
Latest Compugen Ltd. News
CGEN Breaking Stock News: Dive into CGEN Ticker-Specific Updates for Smart Investing
PR Newswire
21 days ago
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Simply Wall St.
a month ago
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
GuruFocus.com
a month ago
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ...
Zacks
a month ago
Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates
Associated Press Finance
a month ago
Compugen: Q3 Earnings Snapshot
PR Newswire
a month ago
Compugen Reports Third Quarter 2024 Results
PR Newswire
a month ago
Compugen to Participate in Stifel 2024 Healthcare Conference
PR Newswire
a month ago
Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
Compare CGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CGEN Compugen Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.